CELLINK today announced that it has received funding from Vinnova for a project in collaboration with ibidi GmbH and NMI (Naturwissenschaftliches und Medizinisches Institut). The project will start in August this year and is expected to run until 2023. CELLINK will receive a grant of approximately two million SEK during the course of the project from Vinnova, a government agency in Sweden that administers state funding for innovative research and development.
The project aims to develop a new organ-like in vitro model of the proximal tubule in a microfluidic perfusable device in multiwell plate format for use in drug development and testing. Complex, scalable and reproducible 3D assembly of the extracellular matrix and cells will be achieved by leveraging bioprinting, novel gel materials, microfluidic chips and an automated periphery system that will be developed and evaluated as part of the project.
In the future, the project can develop a screening system for developing therapies for renal diseases. These diseases affect both men and women, as well as young and elderly individuals.
For more information, please contact:
CELLINK is the leading 3D bioprinter provider and the first bioink company in the world. We focus on developing and commercializing bioprinting technologies to allow researchers to print human organs and tissues for pharmaceutical and cosmetic applications. Founded in 2016 and active in more than 50 countries, CELLINK is changing the future of medicine as we know it. Visit www.cellink.com to learn more. CELLINK is listed on Nasdaq First North Growth Market under CLNK. Erik Penser Bank AB is the company’s certified adviser, available by phone at +46 846 383 00 and by email at: firstname.lastname@example.org.
Följande bilagor finns för nedladdning: